Resource Summary Report

Generated by RRID on Sep 2, 2026

RIP (D94C12) XP Rabbit mAb

RRID:AB_2305314
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3493, RRID:AB_2305314

Antibody Information

URL: http://antibodyregistry.org/AB_2305314

Proper Citation: Cell Signaling Technology Cat# 3493, RRID:AB_2305314

Target Antigen: RIP

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IF-IC, F

Antibody Name: RIP (D94C12) XP Rabbit mAb

Description: This monoclonal targets RIP

Target Organism: monkey, rat, hamster, mouse, human

Clone ID: D94C12

Antibody ID: AB_2305314

Vendor: Cell Signaling Technology

Catalog Number: 3493

Alternative Catalog Numbers: 3493P, 3493T, 3493S

Record Creation Time: 20250820T003512+0000

Record Last Update: 20250820T083945+0000

Ratings and Alerts

No rating or validation information has been found for RIP (D94C12) XP Rabbit mAb.

No alerts have been found for RIP (D94C12) XP Rabbit mAb.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 88 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Huang T, et al. (2026) Macrophage metabolic exhaustion and PANoptotic cell death drive chronic tissue inflammation in rheumatoid arthritis. Immunity, 59(4), 970.

Wu Y, et al. (2026) Inhibiting MDM2 enhances RIPK3-mediated necroptosis and synergizes with immune checkpoint blockade therapy. iScience, 29(5), 115724.

Shanmugam MK, et al. (2026) Bioorthogonal catalytic centres engineered for gastrointestinal stabilization provide oral delivery for the treatment of gastric cancer. Journal of nanobiotechnology, 24(1).

Pan MJ, et al. (2026) Autoinhibitory control of MLKL governs pseudokinase domain phosphorylation and oligomerization during necroptosis. Cell reports, 45(4), 117130.

Wang HL, et al. (2026) Loss-of-Function (G603R) Lrp10 Fails to Downregulate mRNA of Pathologic ?-Synuclein and Causes Neurodegeneration of Substantia Nigra Dopaminergic Cells in Parkinson's Disease Knockin Mice. Neurochemical research, 51(3).

Ishikawa KI, et al. (2026) Suppression of ATM kinase signaling accelerates cellular senescence. Stem cell reports, 21(7), 102956.

Xie X, et al. (2026) Repression of RIPK1 kinase by INPP5D inhibits expression of diverse proinflammatory mediators and late-onset Alzheimer's disease risk factors. Immunity, 59(2), 419.

Li N, et al. (2026) Lyn attenuates cisplatin-induced acute kidney injury by inhibition of RIPK1-mediated apoptosis and necroptosis. Biochemical pharmacology, 251(Pt 1), 118094.

Li J, et al. (2026) Integrating bulk and single-cell transcriptome profiling to uncover diagnostic biomarkers and regulatory mechanisms of oxidative stress in spinal cord injury. Neural regeneration research, 21(6), 2643.

Hasegawa M, et al. (2026) Tolerance to extracellular acidic pH facilitates tumor plasticity. Cell reports, 117226.

Shi FL, et al. (2026) Luteolin mitigates inflammatory organ injury by targeting XIAP to block PANoptosis and mitochondrial dysfunction. International immunopharmacology, 173, 116271.

Su X, et al. (2026) USP25 regulates atherosclerosis by restricting RIPK1-mediated inflammatory responses. EBioMedicine, 126, 106213.

Ehlers L, et al. (2026) ADA2-deficient cells exhibit increased levels of cell death and metabolic disturbances. Cell death discovery, 12(1).

Wang Z, et al. (2026) Remimazolam mitigates cerebral ischemia/reperfusion injury by concurrently alleviating damage to the blood-brain barrier and RIP3/MLKL-driven necroptosis. International immunopharmacology, 172, 116182.

Yeap HW, et al. (2025) A bacterial network of T3SS effectors counteracts host pro-inflammatory responses and cell death to promote infection. The EMBO journal, 44(9), 2424.

Luo C, et al. (2025) Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells. Immunity, 58(3), 745.

Yang H, et al. (2025) 7 I, a structurally modified sinomenine, exerts dual anti-GBM effects by inhibiting glioblastoma proliferation and inducing necroptosis which further mediates lysosomal cell death. British journal of pharmacology, 182(10), 2310.

Guo HX, et al. (2025) SEW2871 attenuates myocyte necroptosis in heart failure through inhibition of oxidative stress and inflammatory cytokines. British journal of pharmacology, 182(12), 2772.

Koerner L, et al. (2025) RIPK1 autophosphorylation at S161 mediates cell death and inflammation. The Journal of experimental medicine, 222(12).

Xia CL, et al. (2025) Identification of the pyroptosis, apoptosis, and necroptosis (PANoptosis) involved in osteogenic differentiation inhibition impaired by tumor necrosis factor-?. European journal of medical research, 30(1), 541.